ClinicalTrials.gg
CompletedNCT06702462Updated Aug 21, 2026Results posted

A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma

A Phase 1 interventional study of HFA-152A propellant and HFA-134A propellant in Asthma, sponsored by GlaxoSmithKline. Completed at 3 sites in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 262 studies in Asthma by GlaxoSmithKline — 7 open to participants now, 12 under way, 7 of them phase 3. Asthma · GlaxoSmithKline.

Enrollment
200th of 238
20 · median 93
Started
2025
with 1 other
Phase 1
62 of 262
1 open now
Registered
254th of 262
by date

Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 200th largest by enrollment of the 238 interventional ones that give a count, is one of 2 that started in 2025, is one of 62 in phase 1, and was the 254th registered.

Asthma

4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 262 studies in Asthma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Asthma by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of the study is to assess the propellants,1 - Difluoroethane [HFA-152a] (Test) and 1,1,1,2-Tetrafluoroethane [HFA-134a] (Reference) for their potential to cause the airways to tighten when delivered through pressurized metered dose inhalers (pMDI). The rationale for this study is to develop a low carbon footprint alternative propellant, HFA-152a, which will have a lower impact on global warming.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • HFA-152a
  • HFA-134a
  • pMDI
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study if all the following criteria apply:

  • Male or female; females may be of , of nonchildbearing potential, or .
  • Participant must be 18 to 45 years of age inclusive, at the time of screening.
  • Confirmed diagnosis of asthma: documented, established diagnosis of asthma for at least 6 months.
  • Receiving 1 of the following asthma treatments, at a stable dose, for at least 12 weeks prior to the screening visit and is anticipated to remain stable for the duration of the study:

    • As needed short-acting beta-agonists (SABA) only
    • As needed SABA plus low-dose Inhaled (ICS) (defined as 100-250 µg/day fluticasone propionate or equivalent taken whenever SABA is taken).
    • Daily maintenance low-dose ICS, plus as needed SABA or ICS-SABA single inhaler combination therapy
    • Low dose combination single inhaler ICS-formoterol or single inhaler ICS-SABA as needed for symptom relief (and if needed, before exercise)
    • Leukotriene receptor antagonist (LTRAs) in combination with any of the above therapies
  • Asthma Control Questionnaire (ACQ)-6 score \<1.5 at screening and Day -1.
  • No severe asthma exacerbations within 6 months prior to screening and ≤1 severe exacerbation during the 12 months prior to screening.
  • Lung function: subjects with a pre-bronchodilator ≥60% predicted at Screening and Day-1.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

    • Is a Woman of non-childbearing potential (WONCBP) OR
    • Is a Woman of childbearing potential (WOCBP) and using a method that is highly effective, with a failure rate of \<1%.
  • Female participants must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 28 days before the first dose of study intervention.
  • For male participants, no contraceptive measures are required.
  • Non-smokers, or previous smokers who have not used any tobacco containing-products or vaping products within 12 months prior to study start, and with a total pack year history of ≤10 pack years.
  • The use of marijuana, even with a valid prescription, is prohibited within 12 months prior to study start.
  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the ICF and protocol.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • A history of life-threatening asthma or asthma that is unstable in the opinion of the investigator.
  • Asthma treatment requiring use of biologic agents (e.g. mepolizumab or dupilumab), chronic systemic , or oral controller agents other than LTRAs.
  • Respiratory disorders other than asthma; A history of respiratory diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, cystic fibrosis, bronchiectasis, interstitial lung disease, emphysema, , tuberculosis and other respiratory abnormalities other than asthma that, in the opinion of the investigator, would put the participant at risk through study participation, or would affect the study analyses if the disease exacerbates and/or requires additional therapy during the study. This includes history of lung cancer and previous thoracic surgery such as lung resection.
  • Asthma Exacerbation: Any severe asthma exacerbation within 6 months prior to screening. (Severe asthma exacerbation defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days, or a single depo injection or an in-patient hospitalization or early discontinuation (ED) visit due to asthma that required systemic corticosteroids).
  • Biologic/ therapies that can be used for the treatment of respiratory diseases during the 6 months, or 5 half-lives whichever is longer-prior to start of the study.
  • Participants undergoing de-sensitization therapy.
  • Administration of systemic, oral, or depot corticosteroids for asthma treatment within 12 weeks of Visit 1. Intranasal corticosteroids are permitted if at a stable dose for at least 3 months prior to screening.
  • Stable doses (3 months or longer) of the following are permitted:

    • Intranasal corticosteroids
    • Oral anti-histamines
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    HFA-152A propellant followed by HFA-134A propellant

    Drug: HFA-152A propellant · Drug: HFA-134A propellant

  • Experimental
    HFA-134A propellant followed by HFA-152A propellant

    Drug: HFA-152A propellant · Drug: HFA-134A propellant

Interventions

  • DrugHFA-152A propellant

    HFA-152A propellant is administered via oral inhalation

  • DrugHFA-134A propellant

    HFA-134A propellant is administered via oral inhalation

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 15 Minutes Post-dose

    FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and measured using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.

    Time frame: Baseline (Day 1, pre-dose) and at 15 minutes post-dose

Secondary outcomes

  1. Area Under the Curve for FEV1 From Time Zero to 15 Minutes (FEV1 AUC0-15 Mins)

    FEV1 was measured using spirometry. AUC was assessed from the first non-missing timepoint to the 15 minute time point.

    Time frame: Up to 15 minutes post-dose

  2. Percentage Change From Baseline in FEV1 at 5, 60, and 180 Minutes Post-dose

    FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and measured using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.

    Time frame: Baseline (Day 1, pre-dose) and at 5, 60, and 180 minutes post-dose

  3. Number of Participants With Percentage Change From Baseline in FEV1 <-15% at Timepoints 5, 15, 60 and 180 Minutes Post-dose

    FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.

    Time frame: Baseline (Day 1, pre-dose) and at 5, 15, 60 and 180 minutes post-dose

  4. Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

    An AE is defined as any untoward medical occurrence in a clinical study participant that was temporally associated with the use of a study intervention, regardless of whether it was related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, or was a congenital anomaly, birth defect, or abnormal pregnancy outcome. SAEs are a subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Time frame: Up to approximately 85 days

07

Results

Posted Aug 21, 2026

Participant flow

Period 1
Participant flow — Period 1
MilestoneSalbutamol HFA-152a (Test) Followed by Salbutamol HFA-134a (Reference)Salbutamol HFA-134a (Reference) Followed by Salbutamol HFA-152a (Test)
Started911
Completed811
Not completed10
Withdrew: Adverse event10
Period 2
Participant flow — Period 2
MilestoneSalbutamol HFA-152a (Test) Followed by Salbutamol HFA-134a (Reference)Salbutamol HFA-134a (Reference) Followed by Salbutamol HFA-152a (Test)
Started811
Completed811
Not completed00

Outcome measures

PrimaryPercentage Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 15 Minutes Post-dose

FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and measured using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.

Time frame:
Baseline (Day 1, pre-dose) and at 15 minutes post-dose
Reported as:
Least squares mean · Percentage change
Percentage Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 15 Minutes Post-dose
Percentage changeSalbutamol HFA-152a (Test)Salbutamol HFA-134a (Reference)
Percentage Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 15 Minutes Post-dose-0.37 (-3.42 to 2.68)-0.60 (-3.65 to 2.44)
Statistical analysis
  • Salbutamol HFA-152a (Test) vs Salbutamol HFA-134a (Reference) · Mixed Models Analysis · p = 0.9047 · Mean difference (net): 0.2325 · 95% CI -3.6051 to 4.0700The analysis was performed using Mixed effect model with the percent change from baseline in FEV1 as the response variable.
SecondaryArea Under the Curve for FEV1 From Time Zero to 15 Minutes (FEV1 AUC0-15 Mins)

FEV1 was measured using spirometry. AUC was assessed from the first non-missing timepoint to the 15 minute time point.

Time frame:
Up to 15 minutes post-dose
Reported as:
Least squares mean · Liter*minutes (L*mins)
Area Under the Curve for FEV1 From Time Zero to 15 Minutes (FEV1 AUC0-15 Mins)
Liter*minutes (L*mins)Salbutamol HFA-152a (Test)Salbutamol HFA-134a (Reference)
Area Under the Curve for FEV1 From Time Zero to 15 Minutes (FEV1 AUC0-15 Mins)48.51 (43.83 to 53.18)49.56 (44.88 to 54.24)
SecondaryPercentage Change From Baseline in FEV1 at 5, 60, and 180 Minutes Post-dose

FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and measured using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.

Time frame:
Baseline (Day 1, pre-dose) and at 5, 60, and 180 minutes post-dose
Reported as:
Least squares mean · Percentage change
Percentage Change From Baseline in FEV1 at 5, 60, and 180 Minutes Post-dose
Percentage changeSalbutamol HFA-152a (Test)Salbutamol HFA-134a (Reference)
Change from baseline (CFB) to 5 mins post-dose1.89 (-1.15 to 4.94)3.64 (0.59 to 6.69)
CFB to 60 mins post-dose0.56 (-2.49 to 3.61)-0.30 (-3.35 to 2.75)
CFB to 180 mins post-dose2.82 (-0.23 to 5.86)0.24 (-2.81 to 3.29)
SecondaryNumber of Participants With Percentage Change From Baseline in FEV1 <-15% at Timepoints 5, 15, 60 and 180 Minutes Post-dose

FEV1 is defined as the volume of air that can be forced out in one second, after taking a deep breath and using spirometry. Baseline is defined as the latest pre-dose assessment with a non-missing value including those from unscheduled visits.

Time frame:
Baseline (Day 1, pre-dose) and at 5, 15, 60 and 180 minutes post-dose
Reported as:
Count of participants · Participants
Number of Participants With Percentage Change From Baseline in FEV1 <-15% at Timepoints 5, 15, 60 and 180 Minutes Post-dose
ParticipantsSalbutamol HFA-152a (Test)Salbutamol HFA-134a (Reference)
5 mins post-dose00
15 mins post-dose01
60 mins post-dose01
180 mins post-dose00
SecondaryNumber of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

An AE is defined as any untoward medical occurrence in a clinical study participant that was temporally associated with the use of a study intervention, regardless of whether it was related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, or was a congenital anomaly, birth defect, or abnormal pregnancy outcome. SAEs are a subset of AEs. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

Time frame:
Up to approximately 85 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
ParticipantsSalbutamol HFA-152a (Test)Salbutamol HFA-134a (Reference)
AE11
SAE00

Adverse events

Collected over All-cause mortality, non-SAEs and SAEs were collected up to approximately 85 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Salbutamol HFA-152a (Test)0/20 (0%)0/20 (0%)1/20 (5%)
Salbutamol HFA-134a (Reference)0/19 (0%)0/19 (0%)1/19 (5.3%)
Most frequent other events
Most frequent other events
EventSalbutamol HFA-152a (Test)Salbutamol HFA-134a (Reference)
RashSkin and subcutaneous tissue disorders0/201/19
DiarrhoeaGastrointestinal disorders1/200/19
UrticariaSkin and subcutaneous tissue disorders1/200/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)Salbutamol HFA-152a (Test) Followed by Salbutamol HFA-134a (Reference)Salbutamol HFA-134a (Reference) Followed by Salbutamol HFA-152a (Test)Total
Mean36.0 ± 8.6630.0 ± 6.5032.7 ± 7.95
Sex: Female, Male
Sex: Female, Male(Participants)Salbutamol HFA-152a (Test) Followed by Salbutamol HFA-134a (Reference)Salbutamol HFA-134a (Reference) Followed by Salbutamol HFA-152a (Test)Total
Female4610
Male5510
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Salbutamol HFA-152a (Test) Followed by Salbutamol HFA-134a (Reference)Salbutamol HFA-134a (Reference) Followed by Salbutamol HFA-152a (Test)Total
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American549
White268
More than one race000
Unknown or Not Reported101
08

Study locations

3 sites
  • GSK Investigational Site
    Marlton, New Jersey 08053, United States
  • GSK Investigational Site
    Huntersville, North Carolina 28078, United States
  • GSK Investigational Site
    San Antonio, Texas 78209, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Jun 2025, 2 months.

Results were first posted in Aug 2026, 1 year 2 months after primary completion.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 2 months is below that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Nov 25, 2024
StartActual
Mar 11, 2025
Primary completionActual
Jun 4, 2025
CompletionActual
Jun 4, 2025
Results first posted
Aug 21, 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06702462
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 25, 2024
Start date
Mar 11, 2025
Primary completion
Jun 4, 2025
Completion
Jun 4, 2025
Results posted
Aug 21, 2026
Last update
Aug 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion